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The asthma is a problem of health with a high prevalence and with important 
implications in the quality of life of the patients. 
In the pharmatherapeutic field, there are multiple alternatives. Due to the 
prevalence of the pathology and its priority in health, it was considered 
indispensable to revise the pharmaceutical offer applying criteria of cost-
effectiveness. Because of that, from the CAEIP the realization of the systematic 
Revision of economic evaluations was in charge of the corticoids inhaled alone or 
associates with adrenergic agonist beta-2 of action prolonged in the treatment of 
the asthma chronic in adults and children over 12 years commercialized in Spain. 
Considering the results of the systematic revision of economic evaluations of the 
inhaled corticoids, alone or associates with agonists adrenergic beta-2 in the 
treatment of the chronic asthma in adults and in children over 12 years1, another 
evidence2 available and the appraisals of the members of the CAEIP, the CAEIP 
recommends the following measures for an efficient selection of medicines for the 
treatment of the chronic asthma in adults and children over 12 years: 
 
• In monotherapy with inhaled corticoids, it recommends the/those of minor 




• In those patients who do not respond to corticoids to high doses, it 
recommends to make the therapeutic change to a suitable combination of 
inhaled corticoids and agonists beta-2 of prolonged action. 
 
                                                 
1 Systematic revision of  economic evaluations about inhaled corticoids, alone or 
associates with agonists adrenergic beta-2 of action prolonged in the treatment of the 
chronic asthma in adults and in children over 12 years. Juan Oliva, Marta Trapero y Mª 
Dolores Fraga. 200 
2  Gema 2009. Spanish guide for asthma management. Madrid 2009 
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• Among the combinations of active principles of inhaled corticoids and 
available beta-2 of prolonged action from the perspective of cost-
effectiveness, there is not enough evidence for recommending an option 
towards the other one. 
 
• That the changes of medication are subordinated to patients badly 
controlled or to those patients where the change of treatment assures a 
good inhalatory technique and fulfillment on the part of the patients. 
 
These recommendations do not have to imply discarding the selection of the 
therapeutic alternative that, according to the clinical criterion, one generates 
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